The 2011 World Orphan Drugs Congress USA took place in Washington DC two weeks ago and was enjoyed by all. Over 200 industry leaders from big pharma, biotechs, government and research organizations came together to address the opportunities and challenges for the commercialization of drugs to treat rare diseases.
Don’t just take our word for it – here are what some of the 2011 attendees had to say:
"It was an honor to attend the World Orphan Drug Congress USA and to be a part of the panel discussion. I enjoyed the conference very much. Congratulations on putting together a program with such excellent speakers covering so many diverse areas involved in the rare disease space. I especially appreciated the collaboration of different players coming together to address the challenges and opportunities before us. This is not typical at other conferences."
Mary Cobb, Senior Vice President, Membership & Organizational Strategy, National Organization for Rare Diseases
"…thank you for a great program and a very good meeting! I learned so much and got to know so many people it was really time well spent!"
Dr. An van Es-Johansson, Head of Clinical Development, Swedish Orphan Biovitrum
"A wonderful opportunity to learn from leaders from biotech and pharma as well as partners in orphan drug development with ample time to network."
Gail Adinamis, Chief Executive Officer, GlobalCare Clinical Trials
"Best conference in this area! Good speakers and grouping of topics – (enjoyed) networking opportunities."
Durhane Wong-Rieger, President, Canadian Organization for Rare Disorders
"Very good, provided us with excellent diverse perspective(s)."
May Orfali, Global Medical Lead – Rare Disease & Hematology, Pfizer
For more information on the 2011 conference, check out the post event report, which includes information on the agenda, sponsors and more.
We are now offering huge savings on 2012 registrations for the World Orphan Drug Congress USA! Save up to $2280, but hurry, this offer is only valid until May 14th!